POTENTIAL THERAPEUTIC APPROACHES TO THE TREATMENT OR PREVENTION OF DIABETIC NEUROPATHY - EVIDENCE FROM EXPERIMENTAL STUDIES

被引:100
作者
CAMERON, NE
COTTER, MA
机构
[1] Department of Biomedical Sciences, University of Aberdeen
关键词
DIABETES-MELLITUS; NEUROPATHY; NERVE BLOOD FLOW; VASODILATOR TREATMENT; POLYOL PATHWAY; OXIDATIVE STRESS; ADVANCED GLYCATION; TROPHIC FACTORS;
D O I
10.1111/j.1464-5491.1993.tb00131.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Recent investigations using experimental models of diabetes mellitus have emphasized the importance of impaired blood flow for the development of nerve dysfunction. Other observations suggest that this may also be the case for patients. A number of studies have revealed that several types of vasodilators can prevent or successfully treat early conduction abnormalities in diabetic rodents. These include alpha1-adrenoreceptor antagonists, calcium channel blockers, agents that inhibit the renin-angiotensin system, and vasomodulator prostanoids. Other treatments applied to animal models, such as omega-6 essential fatty acids, aldose reductase inhibitors, aminoguanidine which prevents the formation of advanced glycation end-products, and anti-oxidants all appear to have vascular-related effects that lead to improvements in nerve conduction. These findings suggest that endothelial dysfunction and oxidative stress could be important factors in the aetiology of diabetic neuropathy. Studies have also focused on deficits in axon growth and regeneration, their relation to impaired neuronal synthesis and transport of growth-related chemicals, and neuronotrophic abnormalities. Taken together, the data give rise to the notion that an optimal therapeutic strategy could consist of improving the microenvironment of damaged nerve fibres by manipulating nerve blood flow while concurrently encouraging repair with trophic agents.
引用
收藏
页码:593 / 605
页数:13
相关论文
共 162 条
  • [1] Sima AAF, Lattimer SA, Yagihashi S., Greene DA., Axoglial dysjunction. A novel structural lesion that accounts for poorly reversible slowing of nerve conduction in the spontaneously diabetic Bio‐Breeding rat, J Clin Invest, 77, pp. 474-484, (1986)
  • [2] Gregerson G., Diabetic neuropathy: influence of age, sex, metabolic control and duration of diabetes on motor conduction velocity, Neurology, 17, pp. 972-980, (1967)
  • [3] Ward JD, Barnes CG, Fisher DJ, Jessop JD, Baker RWR., Improvement in nerve conduction following treatment in newly‐diagnosed diabetics, Lancet, 1, pp. 428-431, (1971)
  • [4] Low PA., Recent advances in the pathogenesis of diabetic neuropathy, Muscle Nerve, 10, pp. 121-128, (1987)
  • [5] Greene DA, Lattimer-Greene S., Sima AAF., Pathogenesis and prevention of diabetic neuropathy, Diabetes Metab Rev, 4, pp. 201-221, (1988)
  • [6] Boulton AJM., Pathogenesis of diabetic neuropathy, The Diabetes Annual, 7, pp. 192-210, (1993)
  • [7] Tomlinson DR., The pharmacology of diabetic neuropathy, Diabetes Metab Rev, 8, pp. 67-84, (1992)
  • [8] Watkins PJ., Clinical observations and experiments in diabetic neuropathy, Diabetologia, 35, pp. 2-11, (1992)
  • [9] Dvornik D., Aldose Reductase Inhibition, (1987)
  • [10] Horrobin DF., The roles of essential fatty acids in the development of diabetic neuropathy and other complications of diabetes mellitus, Prostaglandins Leukotrienes Essen Fatty Acids, 31, pp. 181-197, (1988)